克拉屈滨对多发性硬化中T细胞和B细胞及T细胞反应性的影响
这项横断面探索性研究比较了未治疗与接受克拉屈滨治疗1年的复发缓解型多发性硬化患者外周T、B细胞亚群及对中枢神经系统抗原的反应性,发现治疗1年后CD4+ T细胞数量持续偏低而CD19+ B细胞计数正常化,滤泡辅助T细胞及产生B细胞辅助细胞因子的效应亚群减少,B细胞池偏向初始和抗炎表型,对RASGRP2的反应性降低。
要点
- 克拉屈滨治疗1年后CD4+ T细胞数量持续低于未治疗患者,而CD19+ B细胞计数正常化。
- 滤泡辅助T细胞及其产生B细胞辅助细胞因子的效应亚群减少,B细胞池偏向初始和抗炎表型。
- 对中枢神经系统富集自身抗原RASGRP2的反应性降低,对髓鞘碱性蛋白和髓鞘少突胶质细胞糖蛋白无此变化。
核心结论
- 克拉屈滨治疗损害B-T细胞交互并降低其介导致病性效应功能的能力,可能导致对表达于B细胞和脑组织的RASGRP2自身反应性的特异性降低。
研究设计与样本
- 横断面探索性研究,采用流式细胞术检测未治疗和接受克拉屈滨治疗1年的复发缓解型多发性硬化患者外周T、B细胞亚群频率和绝对计数及B细胞细胞因子产生,并用FluoroSpot试验评估自身反应性。
主要发现
- 克拉屈滨治疗1年后,CD4+ T细胞数量持续低于未治疗复发缓解型多发性硬化患者,而CD19+ B细胞计数正常化。
- 滤泡辅助T细胞及产生不同B细胞辅助活性细胞因子的效应亚群减少,外周B细胞池偏向初始和抗炎表型。
- 克拉屈滨治疗患者对RASGRP2的反应性降低,对髓鞘碱性蛋白和髓鞘少突胶质细胞糖蛋白的反应性未降低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Cladribine tablet therapy is an efficacious treatment for multiple sclerosis (MS), however, its mechanism of action on T and B cell subsets remains unclear. The purpose of this study was to investigate the treatment effects of cladribine on the peripheral pool of T and B cells subsets and reactivity toward central nervous system (CNS) antigens. METHODS: In this cross-sectional exploratory study, frequencies and absolute counts of peripheral T and B cell subsets and B cell cytokine production from untreated patients with relapsing-remitting MS (RRMS) and patients treated with cladribine for 1 year were measured using flow cytometry. Autoreactivity was assessed using a FluoroSpot assay. RESULTS: We found that 1 year after initiation of cladribine treatment, a lower number of CD4+ T cells was persisting whereas CD19+ B cell counts were normalized compared to untreated patients with RRMS. Follicular helper T cells and their effecter subsets producing cytokines exerting distinct B cell helper activity were lower and, additionally, the peripheral B cell pool was skewed toward a naïve and anti-inflammatory phenotype. Finally, reactivity to the recently identified CNS-enriched autoantigen RAS guanyl-releasing protein 2 (RASGRP2), but not to myelin basic protein and myelin oligodendrocyte glycoprotein, was lower in cladribine-treated patients. INTERPRETATION: Together, these investigations on T and B cell subsets suggest that cladribine treatment impairs the B-T cell crosstalk and reduces their ability to mediate pathogenic effector functions. This may result in specific reduction of autoreactivity to RASGRP2 which is expressed in B cells and brain tissue. ANN NEUROL 2023;94:518-530.
引用
- Holm Hansen R, von Essen MR, Mahler MR, et al. Cladribine Effects on T and B Cells and T Cell Reactivity in Multiple Sclerosis. Ann Neurol. 2023. PMID: 37191113. doi:10.1002/ana.26684
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。